Bharat Biotech International Limited (BBIL), a pioneer in affordable indigenous vaccine development and manufacturing, ...

Bharat Biotech aims to democratize gene therapies, traditionally considered prohibitively expensive and available primarily ...

OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category Oxford, UK – 21 March 2025: OXB (LSE: ...

Vaccine manufacturer Bharat Biotech International Limited (BBIL) is making a foray into the cell and gene therapy (CGT) space ...

DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...

ViroCell Biologics ("ViroCell" or the "Company"), a cell and gene therapy ("CGT") contract development and manufacturing organization ("CDMO") specializing in GMP viral vector manufacturing for ...

In a groundbreaking advancement for families grappling with the challenges of Dravet syndrome, a rare and life-altering form ...

Bharat Biotech invests $75 million in India's first Cell & Gene Therapy facility, focusing on advanced therapies and ...

The first-of-its-kind facility in India has received an investment of $75 million from the company to build it vertically ...

Our CGT facility is designed to produce high-titer viral vectors (AAV, Lentivirus, Adenovirus), which are essential for cell and gene therapy applications - the crucial material for anti-cancer ...